OnKure Therapeutics (OKUR) Competitors $8.61 -0.12 (-1.37%) (As of 12/18/2024 05:44 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends OKUR vs. IVA, LPTX, VERU, RGLS, DERM, ANRO, BHST, IMUX, CNTX, and SKYEShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Inventiva (IVA), Leap Therapeutics (LPTX), Veru (VERU), Regulus Therapeutics (RGLS), Journey Medical (DERM), Alto Neuroscience (ANRO), BioHarvest Sciences (BHST), Immunic (IMUX), Context Therapeutics (CNTX), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical preparations" industry. OnKure Therapeutics vs. Inventiva Leap Therapeutics Veru Regulus Therapeutics Journey Medical Alto Neuroscience BioHarvest Sciences Immunic Context Therapeutics Skye Bioscience Inventiva (NASDAQ:IVA) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings. Do analysts prefer IVA or OKUR? Inventiva currently has a consensus target price of $13.25, indicating a potential upside of 481.14%. OnKure Therapeutics has a consensus target price of $36.00, indicating a potential upside of 318.12%. Given Inventiva's higher possible upside, equities analysts clearly believe Inventiva is more favorable than OnKure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Which has more volatility and risk, IVA or OKUR? Inventiva has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Do insiders and institutionals have more ownership in IVA or OKUR? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer IVA or OKUR? In the previous week, Inventiva had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for Inventiva and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.81 beat Inventiva's score of 0.38 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, IVA or OKUR? OnKure Therapeutics has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$15.62M7.66-$119.51MN/AN/AOnKure TherapeuticsN/AN/A-$77.39M-$12.20-0.71 Is IVA or OKUR more profitable? Inventiva's return on equity of 0.00% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A OnKure Therapeutics N/A -51.17%-47.11% Does the MarketBeat Community prefer IVA or OKUR? Inventiva received 15 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 80.00% of users gave Inventiva an outperform vote. CompanyUnderperformOutperformInventivaOutperform Votes2080.00% Underperform Votes520.00% OnKure TherapeuticsOutperform Votes5100.00% Underperform VotesNo Votes SummaryInventiva beats OnKure Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.78M$6.71B$5.03B$8.97BDividend YieldN/A3.07%4.80%4.06%P/E Ratio-0.7110.45134.6616.92Price / SalesN/A187.361,125.95116.20Price / CashN/A57.1640.5137.94Price / Book0.325.194.744.71Net Income-$77.39M$151.85M$118.37M$225.20M7 Day Performance-20.50%-5.29%12.10%-2.58%1 Month Performance-47.47%-4.63%9.99%3.57%1 Year PerformanceN/A9.45%30.12%16.54% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.9426 of 5 stars$8.61-1.4%$36.00+318.1%N/A$28.78MN/A-0.71N/AHigh Trading VolumeIVAInventiva3.1763 of 5 stars$2.32-5.3%$13.25+471.1%-47.9%$121.75M$15.62M0.00100LPTXLeap Therapeutics1.4072 of 5 stars$3.02+2.4%$7.50+148.3%-3.8%$115.73M$1.50M-1.5340VERUVeru2.0572 of 5 stars$0.74+2.4%$4.00+440.5%-1.5%$108.32M$14.09M-1.51189Earnings ReportGap UpRGLSRegulus Therapeutics2.8292 of 5 stars$1.65+4.4%$10.80+554.5%+22.8%$108.08MN/A-1.4830News CoveragePositive NewsDERMJourney Medical2.206 of 5 stars$5.00-1.8%$9.38+87.5%N/A$104.45M$79.18M-5.4190ANROAlto Neuroscience3.3099 of 5 stars$3.85+0.5%$20.00+419.5%N/A$103.83M$210,000.000.00N/AGap UpBHSTBioHarvest SciencesN/A$6.31+2.6%$14.00+121.9%N/A$103.64M$22.43M-4.92N/AAnalyst ForecastNews CoverageIMUXImmunic2.7861 of 5 stars$1.15+1.3%$11.80+930.6%-28.0%$103.14MN/A-0.9270Positive NewsGap UpCNTXContext Therapeutics2.9632 of 5 stars$1.37-1.4%$6.80+396.4%+18.4%$102.75MN/A-1.477Short Interest ↓Positive NewsSKYESkye Bioscience2.2275 of 5 stars$3.38+0.9%$18.67+452.3%+5.4%$102.54MN/A0.0011Positive NewsGap Down Related Companies and Tools Related Companies Inventiva Alternatives Leap Therapeutics Alternatives Veru Alternatives Regulus Therapeutics Alternatives Journey Medical Alternatives Alto Neuroscience Alternatives BioHarvest Sciences Alternatives Immunic Alternatives Context Therapeutics Alternatives Skye Bioscience Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OKUR) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKUR Stock Alerts